Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FES PET/MRI in Endometriosis
NCT04382911Phase 2Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Aug 2020
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of fluoroestradiol f 18 in endometriosis, sponsored by University of North Carolina at Chapel Hill. Primary endpoints: Sensitivity of FES PET/MRI for Evaluating Endometriosis at 2 hours and Specificity of FES PET/MRI for Evaluating Endometriosis at 2 hours. Started Aug 2020; status: completed.
02
Drugs
fluoroestradiol f 18
03
Conditions
endometriosis
Beyond the preview
Go deeper on NCT04382911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04382911.